Details of the Drug Combination

General Information of Drug Combination (ID: DCLHA99)

Drug Combination Name
Lithium Citrate GSK2194069
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Lithium Citrate   DMXAVX5 GSK2194069   DMZ2TD9
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL is unavailable
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 1.78
Bliss Independence Score: 1.78
Loewe Additivity Score: 14.79
LHighest Single Agent (HSA) Score: 14.81

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Lithium Citrate
Disease Entry ICD 11 Status REF
Bipolar disorder 6A60 Approved [2]
Indication(s) of GSK2194069
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [3]
GSK2194069 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Fatty acid synthase (FASN) TT7AOUD FAS_HUMAN Inhibitor [3]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 A human fatty acid synthase inhibitor binds beta-ketoacyl reductase in the keto-substrate site. Nat Chem Biol. 2014 Sep;10(9):774-9.